Experience

Beacon Pharmaceuticals Limited

• Bangladesh
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Assistant Manager

  • Jan 2023 - Present

• Junior Assistant Manager

  • Jan 2022 - Dec 2022

  ## Immunotherapy PortfolioIn 2022 I have been promoted as Jr. Asst. Manager to develop and expand a new market segment, IMMUNOTHERAPY, in oncology sector. Currently this portfolio consists of two biosimilar, immune checkpoint inhibitor molecules- Pembrolizumab (PEMRO) and Nivolumab (NIVOMAB).## Current Responsibilities- Developing and implementing new strategies to create new prescribers for Immunotherapy- C2C communications to analyze the positioning of the molecules and feedbacks of efficacies- Developing new product pipeline to enlarge the portfolio- Besides got a team member to manage who is looking after my previous portfolio

• Senior Product Executive (Oncology)

  • Jan 2020 - Dec 2021

  ## Managed Molecules:Gemcitabine (Gemoxen), Pembrolizumab (Pemro), Nab-Paclitaxel (Nab-Xelpac), Olaparib (Olapar), Bicalutamide (Bical), Anastrozole (Anastrol), Letrozol (Lexel), Tamoxifen (Tamoxi). The portfolio was consisted with a conventional chemotherapy- Gemcitabine and few other hormone therapies for cancer treatment. Major brand was Gemoxen (Gemcitabine), Pemro (Pembrolizumab).## Achievements- Added values to Gemoxen for ensuring patient benefit and to keep the brand vibrant in the market.- Gemoxen still was the number #1 brand in Gemcitabine market by competing with originator and generic brands by confirming 50% market share (2020-2021).- In 2020 I had launched the 1st ever PARP Inhibitor Olaparib in Bangladesh market in the brand name of Olapar. This molecule has vital roles in Ovarian Cancer, Pancreatic Cancer and Breast Cancer.- Nab-Xelpac, the choice of molecule for Triple Negative Breast Cancer (TNBC), was added to my portfolio in 2021 for brand development. Within 2022 Nab-Xelpac had observed a 50% market growth and KBL number was increased from 10 to 30.- 2021 was a remarkable year. In the history of Bangladesh cancer market a revolution was made on this year. A new treatment, IMMUNOTHERAPY, was launched on 26 March 2021 on the eve of 50th Independence Day of Bangladesh. For the first time I had launched generic, biosimilar, bilogical molecules PEMBROLIZUMAB (Pemro) and NIVOLUMAB (Nivomab) in Bangladesh market.

• Executive (Oncology)

  • Feb 2018 - Dec 2019

  ## Managed Molecules:Gemcitabine (Gemoxen), Bicalutamide (Bical), Anastrozole (Anastrol), Letrozol (Lexel), Tamoxifen (Tamoxi). The portfolio was consisted with a conventional chemotherapy- Gemcitabine and few other hormone therapies for cancer treatment. Major brand was Gemoxen (Gemcitabine).## Achievements:- Building Gemoxen as a trusted and 1st choice of brand in prescriptions.- Under my management Gemoxen had 60% market share (2018-2019).- Being the major market share holder Gemoxen was in the leading position of Gemcitabine market.- Gemoxen was the 2nd leading brand of Beacon Oncology.## International Conferences- In 2018 attended 13th Scientific Conference of SAARC Federation of Oncologists (SFO) in Bhutan- In 2019 attended 4th Annual Meeting of Federation of Asian Organization for Radiation Oncologists (FARO) in China


North South University
• Bangladesh
• Higher Education
• 1 - 100 Employee
• Research Student

  • Aug 2016 - Aug 2017